Trump’s tariff trap for generic drugs

Donald Trump has decided that the pharmaceutical supply chain, like so many other things in his view, should be reorganised by threat and deadline. Imported generic drugs will enter the United States tariff-free from August 1 for two years, then face a 100% tariff for one year and 200% thereafter. The message is hard to miss: build in America, or pay for the privilege of not doing so.

The president said the measure is meant to reshape generic pharmaceutical production in the United States. On Truth Social, he framed it as a way to bring production back onshore and punish companies that do not invest in plants and equipment within the period he has now set. That is vintage Trump: industrial policy with a hammer in one hand and a stopwatch in the other.

The numbers matter because generics are not a niche market. According to the US Food and Drug Administration, more than 90% of medicines sold in the US are generics. So while the policy sounds technical, it touches the bulk of the country’s drug supply. For patients and distributors, that is not a footnote. It is the point.

Trump has also been leaning on drugmakers through his most-favoured-nation pricing policy, which aims to bring US prices closer to those paid in other high-income countries. In his telling, lower prices and domestic production belong in the same package. In practice, the government is trying to squeeze the industry from two sides at once: price pressure on one side, tariff pressure on the other. The pharmaceutical sector, naturally, is expected to applaud the efficiency of being squeezed.

The policy does not apply to patented, branded or innovative drugs, which Trump said will remain unchanged. That distinction is not trivial. The White House is targeting the low-margin, high-volume part of the market while leaving the more lucrative branded segment outside this particular salvo. Last year, the world’s biggest drugmakers already signed deals with the US government that exempted billions of dollars of drugs from tariffs.

Trump had already used tariffs on branded pharmaceuticals in an executive order signed in April, setting a 100% levy unless manufacturers agree to government pricing deals or commit to making their products domestically. The new announcement extends the same logic to generics, though with a delayed start and a harsher endgame. Washington, in other words, is not so much managing trade as trying to legislate industrial loyalty.

Whether this produces more factories or merely more paperwork is the obvious question. The administration is betting that foreign producers will move quickly enough to avoid the later tariff wall. Companies, meanwhile, will calculate whether the American market is worth the cost of compliance. That is how policy is supposed to work in a market economy: clear incentives, not permanent theatre. Then again, Washington has never been shy about dressing theatre up as strategy.

Written by Thorben Thiede thorben.thiede@alpineweekly.com